|
Fresolimumab (GC1008) is a human monoclonal antibody〔(WHO Drug Information )〕 and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer〔(National Cancer Institute: Fresolimumab )〕〔(Statement On A Nonproprietary Name Adopted By The USAN Council – Fresolimumab )〕 (kidney cancer and melanoma). It binds to and inhibits all isoforms of the protein transforming growth factor beta (TGF-β).〔 ==History== Fresolimumab was discovered by Cambridge Antibody Technology (CAT) scientists and was one of a pair of candidate drugs that were identified for the treatment of the fatal condition scleroderma. CAT chose to co-develop the two drugs metelimumab (CAT-192) and fresolimumab with Genzyme. During early development, around 2004, CAT decided to drop development of metelimumab in favour of fresolimumab.〔http://www.independent.co.uk/news/business/news/cat-may-abandon-skin-drug-after-trial-results-disappoint-569445.html〕 In February 2011 Sanofi-Aventis agreed to buy Genzyme for US$ 20.1 billion.〔http://www.bbc.co.uk/news/business-12477750〕 the drug was being tested in humans (clinical trials) against IPF, renal disease, and cancer.〔http://www.genengnews.com/gen-news-highlights/scientists-trigger-white-fat-to-become-brown-fat-like-to-treat-obesty-and-type-2-diabetes/81245389/〕〔(Clinicaltrials.gov for Fresolimumab )〕 On 13 August 2012, Genzyme applied to begin a Phase 2 clinical trial in primary focal segmental glomerulosclerosis〔http://clinicaltrials.gov/show/NCT01665391〕 comparing fresolimumab versus placebo. , Sanofi-Aventis continue to list fresolimumab in their research and development portfolio under Phase II development.〔http://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「fresolimumab」の詳細全文を読む スポンサード リンク
|